Cancer drug improves vision loss in diabetics, cataract surgery patients
August 1st, 2009 - 4:44 pm ICT by ANIWashington, Aug 1 (ANI): Researchers have found that bevacizumab medication, used to treat cancer, can help improve vision loss in diabetic patients as well as in people who have undergone cataract surgery.
Use of bevacizumab (Avastin) can benefit diabetic patients with macular edema as well as people who develop cystoid macular edema after cataract surgery.
Diabetic retinopathy (DR) is the major threat to vision in working-age people.
In type 2 diabetes patients, retinopathy vision loss most often results from macular edema (DME), swelling and thickening of the macula in the retina’s centre.
Laser treatment is usually able to reduce vision loss, but widespread, diffuse DME (DDME) is often resistant to laser and other standard treatments.
The researchers looked at 115 patients who were treated with bevacizumab (Avastin), an anti-vascular endothelial growth factor (anti-VEGF) medication that inhibits abnormal blood vessels.
The researchers revealed that within one month of the initial intravitreal bevacizumab (IVB) injections, improvement could be detected.
By the end of the 24 month follow-up period vision had improved in 51.8 percent of eyes, and 97.1 percent of eyes were either stable or improved.
Lead researcher Dr J. Fernando Arevalo, of the Caracas Central Ophthalmologic Clinic, Venezuela also reviewed the use of bevacizumab in patients with post-cataract surgery cystoid macular edema (CME).
Nearly 72.2 percent of the eyes improved and 27.8 percent remained stable
Macular thickness also decreased in most eyes. Patients who received two or more injections were significantly more likely to improve.
“Large, randomized controlled clinical trials are needed to confirm IVB’s efficacy and safety in treating these conditions,” said Arevalo.
“The results for DMME are very promising and suggest that combining anti-VEGF treatment with laser therapy may prove useful.
“Also, once further study is completed, unresolved CME post-cataract surgery should be considered for inclusion as an indication for use of IVB,” he added.
The study appears in the journal of the American Academy of Ophthalmology. (ANI)
- Blinding disease drug shows promise for diabetic retinopathy patients - Apr 28, 2010
- Steroid jabs may delay diabetes-related eye disease progression - Dec 15, 2009
- Cataract surgery improves mood, sleep in Alzheimer's - Oct 26, 2011
- Drug for bowel cancer can treat eye disease - Jun 14, 2010
- Steroid injections offer 'vision restoration' hope for patients with blocked eye veins - Sep 15, 2009
- Drug therapy shows promise in treating leading cause of childhood blindness - Feb 17, 2011
- Inexpensive drug to prevent sight loss shown to be safe, effective - Jun 11, 2010
- Blue light-filtering lens may protect against age-related vision loss - Oct 27, 2009
- Laser system shows promise for cataract surgery - Nov 18, 2010
- Eye problem cases have increased, say doctors - Oct 12, 2011
- Lasers open way to safer, better cataract operations - Nov 18, 2010
- Can video games help people with cataract? - Feb 17, 2012
- Fake eye drug affects over 60 Chinese - Sep 24, 2010
- Pine bark extract may help treat early diabetic retinopathy - Dec 03, 2009
- Novel cell therapy slows down vision loss in eye disease - Apr 08, 2011
Tags: abnormal blood vessels, avastin, bevacizumab, bevacizumab avastin, cancer drug, cataract surgery, centre laser, diabetes patients, diabetic patients, diabetic retinopathy, edema, fernando arevalo, laser therapy, laser treatment, macula, ophthalmologic, surgery patients, type 2 diabetes, vascular endothelial growth factor, vision loss